Patients with life-threatening allergies need immediate access to injectable epinephrine. But over time, the brand-name epinephrine auto-injector pens that make it easy to quickly and safely administer the medication have become increasingly expensive.
We recognized the urgent need for a less-expensive epinephrine auto-injector, and are proud to offer a low-cost option at all CVS Pharmacy locations. Patients can now purchase the authorized generic for Adrenaclick® at a cash price of $109.99 for a two-pack – the lowest cash price in the market. This authorized generic is a Food and Drug Administration (FDA)-approved device with the same active ingredient as other epinephrine auto-injector devices.
The resources on this page describe patients’ options for epinephrine auto-injectors.
Frequently Asked Questions
Are the EpiPen® auto-injector and the authorized generic for Adrenaclick® approved by the FDA?
Both the EpiPen auto-injectors and the authorized generic of Adrenaclick are approved by the Food and Drug Administration and contain the same active ingredient as other epinephrine auto-injector devices. In addition, the American Academy of Allergy, Asthma, and Immunology includes generic Adrenaclick among therapeutic options in an anaphylaxis emergency action plan1.
How can a patient switch a prescription from EpiPen to the lowest-cost epinephrine auto-injector?
First, the patient should speak with his or her prescriber about whether the authorized generic for Adrenaclick is a good fit for their specific medical needs. The prescriber can then write a prescription for an “epinephrine auto-injector” to ensure the lowest-cost product is filled. Patients who already have a prescription on file with CVS Pharmacy can ask their pharmacist to check with the prescriber about making the change.
How does this affect patients who have insurance?
Our pharmacy staff is always available to help patients understand their medication costs under various health insurance and discount plans. This includes exploring every opportunity to enable patients to reduce their out-of-pocket costs by seeking cheaper but effective generic alternatives. In addition to reducing costs for cash-paying customers, these activities can be beneficial to insured patients who have consumer-directed health plans and have not yet met their deductible for the plan year.
EpiPen® is the registered trademark of Mylan Inc. Adrenaclick® is the registered trademark of Lineage Therapeutics, Inc., which is a wholly-owned subsidiary of Impax Laboratories, Inc.
1 American Academy of Allergy, Asthma & Immunology